St. Jude Medical, Inc. (now part of Abbott Laboratories) CEO Net Worth

Last Updated Mar 10, 2025
CEO NameRobert B. Ford
NationalityUnited States
Net Worth Estimation$55 million

Robert B. Ford, current CEO of Abbott Laboratories (which acquired St. Jude Medical, Inc.), has an estimated net worth of around $55 million largely due to compensation packages, stock grants, and long-term incentives accumulated since joining Abbott in 1996 and becoming CEO in 2020. His financial standing reflects publicly disclosed SEC filings, stock performance, and executive bonuses characteristic of Fortune 100 healthcare companies.

Robert B. Ford's estimated net worth of $55,000,000 is midway between the minimum ($10,000,000) and maximum ($90,000,000) CEO net worths in the healthcare sector. His net worth represents 62.5% of the category's maximum CEO net worth.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Robert B. Ford Performance in St. Jude Medical, Inc. (now part of Abbott Laboratories)

Robert B. Ford, CEO of St. Jude Medical, Inc. (now part of Abbott Laboratories), demonstrated strategic leadership by steering the company through its acquisition, focusing on innovation and operational efficiency. His decision-making emphasized integrating advanced medical technologies and expanding global market presence, enhancing the company's competitive positioning. Ford's performance significantly contributed to Abbott's diversified portfolio and growth, reinforcing its leadership in cardiovascular and medical device sectors.


Latest News

Abbott Completes $25 Billion Acquisition of St. Jude Medical, Enhancing Cardiovascular Device Portfolio

Abbott Laboratories finalized its $25 billion acquisition of St. Jude Medical in January 2017, creating a leading medical device company with top positions in cardiovascular and neuromodulation markets. Abbott CEO Miles D. White highlighted the combined company's extensive product pipeline and market reach, with former St. Jude CEO Michael Rousseau becoming president of Abbott's cardiovascular and neuromodulation division.
Source: http://www.dicardiology.com/content/abbott-completes-acquisition-st-jude-medical



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about St. Jude Medical, Inc. (now part of Abbott Laboratories) are subject to change from time to time.

Comments

No comment yet